Verndari is pioneering a novel vaccination platform with its flagship product, the VaxiPatch™, which utilizes intradermal microarray technology. This innovative single-dose vaccination kit is designed to enhance the efficacy of vaccines for both existing and emerging infectious diseases. The VaxiPatch™ is engineered to be dose-sparing and pain-free, eliminating the need for cold chain shipping and storage, which significantly streamlines the logistics of vaccine distribution. The application process is user-friendly; the patch is placed on the wrist, and a simple pressure mechanism activates the microarray tips to deliver the vaccine directly into the skin, targeting immune cells efficiently.

The VaxiPatch™ features a proprietary microneedle design that ensures precise dosing and is integrated into a single-use applicator for ease of use. Verndari emphasizes high-speed, high-volume automated manufacturing capabilities, utilizing low-cost materials such as medical-grade stainless steel. The company is committed to adhering to Good Manufacturing Practices (GMP) through automated, aseptic fill/finish systems, ensuring that the VaxiPatch™ meets industrial-scale production and commercial logistics requirements. This innovative approach positions Verndari as a leader in the development of advanced vaccination technologies.

United States

Verndari was founded to advance global health by reinventing the vaccination process.Verndari, Inc. developed its patented VaxiPatch™, a complete vaccination kit that can be applied to the back of the wrist or arm. The kit contains a wipe to clean the vaccination site, the VaxiPatch™ device, and a spot bandage to cover the site post-vaccination. After vaccine administration, the VaxiPatch™ is simply peeled off the skin.The company is currently working to develop a vaccine candidate for COVID-19/

Verndari

Company Details